{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:27:43Z","timestamp":1790731663173,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.seizure.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:20:04Z","timestamp":1776234004000},"page":"185-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cenobamate: A comprehensive review"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4823-0537","authenticated-orcid":false,"given":"David G","family":"Vossler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5609-0362","authenticated-orcid":false,"given":"Raman","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0002","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0003","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0004","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.seizure.2026.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2026.04.011_bib0006","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1535759720903032","article-title":"Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial","volume":"20","author":"Vossler","year":"2020","journal-title":"Epilepsy Curr"},{"issue":"11","key":"10.1016\/j.seizure.2026.04.011_bib0009","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/epi.16718","article-title":"Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight into its mechanism of action?","volume":"61","author":"Guignet","year":"2020","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/epi.16832","article-title":"The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ?","volume":"62","author":"L\u00f6scher","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.seizure.2025.11.010","article-title":"Exploration of the mechanism of action of cenobamate","volume":"134","author":"Sankar","year":"2026","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410350216","article-title":"Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors","volume":"35","author":"Rho","year":"1994","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)","volume":"103","author":"Bialer","year":"2013","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0014","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2018.1386553","article-title":"A resurging boom in new drugs for epilepsy and brain disorders","volume":"11","author":"Younus","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.seizure.2026.04.011_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.phrs.2015.12.011","article-title":"Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development","volume":"104","author":"Zaccara","year":"2016","journal-title":"Pharmacological Research"},{"issue":"10","key":"10.1016\/j.seizure.2026.04.011_bib0016","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14656566.2025.2517352","article-title":"Potential of cenobamate as a broad-spectrum antiseizure medication","volume":"26","author":"Melnick","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.seizure.2026.04.011_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18920","article-title":"Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents","volume":"9","author":"Melnick","year":"2023","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.seizure.2026.04.011_bib0018","first-page":"13","article-title":"Pharmacology of emerging selective sodium channel antagonists for the treatment of epilepsy","volume":"24","author":"Sankar","year":"2025","journal-title":"Pract Neurol"},{"key":"10.1016\/j.seizure.2026.04.011_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"855","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.seizure.2026.04.011_bib0020","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult Dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0021","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/acschemneuro.3c00757","article-title":"Molecular pharmacology of selective Na(V)1.6 and dual Na(V)1.6\/Na(V)1.2 channel inhibitors that suppress excitatory neuronal activity ex vivo","volume":"15","author":"Goodchild","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0022","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/life13051191","article-title":"Voltage-gated sodium channel dysfunctions in neurological disorders","volume":"13","author":"Barbieri","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.seizure.2026.04.011_bib0023","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72468","article-title":"NBI-921352, a first-in-class, Na(V)1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats","volume":"11","author":"Johnson","year":"2022","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0024","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.18257","article-title":"Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy","volume":"66","author":"Gjerulfsen","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.950171","article-title":"Real-world experience treating pediatric epilepsy patients with cenobamate","volume":"13","author":"Makridis","year":"2022","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2026.04.011_bib0026","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/jcm13102757","article-title":"Cenobamate plasma levels in patients with epilepsy: correlation with efficacy and tolerability?","volume":"13","author":"Steinhoff","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.seizure.2026.04.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173117","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"879","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0028","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1212\/WNL.0000000000007894","article-title":"Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)","volume":"93","author":"Kasteleijn-Nolst Trenit\u00e9","year":"2019","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.seizure.2026.04.011_bib0029","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0031","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/epi.18698","article-title":"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of adjunctive cenobamate in Asian patients with focal seizures","volume":"67","author":"Lee","year":"2026","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0032","series-title":"Presented at: American Epilepsy Society Annual Meeting, December 5-9","article-title":"Efficacy and safety of adjunctive cenobamate for the treatment of primary generalized tonic-clonic seizures in adults and adolescents [poster]","author":"Shih","year":"2025"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0033","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2026.04.011_bib0034","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2026.04.011_bib0035","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106952","article-title":"Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study","volume":"184","author":"Abou-Khalil","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.04.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.107014","article-title":"Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency","volume":"186","author":"Aboumatar","year":"2022","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.seizure.2026.04.011_bib0038","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/epi.17724","article-title":"Sustainability of seizure reduction and seizure control with adjunctive cenobamate: post-hoc analysis of a phase 3, open-label study","volume":"64","author":"Vossler","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0039","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40266-024-01102-3","article-title":"Safety and efficacy of cenobamate for the treatment of focal seizures in older patients: post hoc analysis of a phase III, multicenter, open-label study","volume":"41","author":"O'Dwyer","year":"2024","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0040","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.70012","article-title":"Early response rates with adjunctive cenobamate in uncontrolled focal seizures: prospective analysis of a randomized, double-blind, placebo-controlled study in a multinational Asian population","volume":"670","author":"Kawai","year":"2026","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0041","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2025.09.021","article-title":"Efficacy of adjunctive cenobamate by focal seizure subtypes: a randomized, double-blind, placebo-controlled, multicenter study in a multinational Asian population","volume":"133","author":"Wu","year":"2025","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.seizure.2026.04.011_bib0042","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/epi.17007","article-title":"Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study","volume":"62","author":"French","year":"2021","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2026.04.011_bib0043","doi-asserted-by":"crossref","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","article-title":"Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"99","author":"Klein","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2026.04.011_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106940","article-title":"Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study","volume":"183","author":"Rosenfeld","year":"2022","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2026.04.011_bib0044","article-title":"Cenobamate add-on therapy for drug-resistant focal epilepsy","volume":"8","author":"Brigo","year":"2024","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/cpdd.1077","article-title":"A phase 1 clinical study evaluating the effects of cenobamate on the QT Interval","volume":"11","author":"Darpo","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0047","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0049","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a 'real-world' retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.109054","article-title":"Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain","volume":"139","author":"Villanueva","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.seizure.2026.04.011_bib0051","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1111\/epi.18091","article-title":"Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program","volume":"65","author":"Roberti","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0052","article-title":"A French real-world experience with cenobamate in patients with drug-resistant focal epilepsy: a retrospective observational study","volume":"31","author":"Plaquevent","year":"2025","journal-title":"Epilepsy Behav Rep"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0053","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/epi.70006","article-title":"Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: a real-world retrospective study in Spain","volume":"67","author":"S\u00e1nchez-Caro","year":"2026","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0054","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/epi4.70021","article-title":"Real-world effectiveness and tolerability of cenobamate in drug-resistant epilepsy: a retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom","volume":"10","author":"Rheims","year":"2025","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0055","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/epi.18297","article-title":"Real-world use of cenobamate in adults: efficacy and predictors of treatment response","volume":"66","author":"Loushy","year":"2025","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2026.04.011_bib0056","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/epi.18357","article-title":"Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: interim results after 24-week observational period from the BLESS study","volume":"66","author":"Lattanzi","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0057","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2025.05.002","article-title":"Efficacy and safety of cenobamate: a multicenter, retrospective evaluation of real-world clinical practice","volume":"130","author":"Bosak","year":"2025","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0058","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/epi4.12757","article-title":"Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program","volume":"8","author":"Villanueva","year":"2023","journal-title":"Epilepsia Open"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0059","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/epi4.70157","article-title":"Using cenobamate for managing idiopathic generalized epilepsy: a single-center experience and systematic literature review","volume":"10","author":"Woodrich","year":"2025","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0060","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/epi.17506","article-title":"Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy","volume":"64","author":"Laskier","year":"2023","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0061","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/epi.17874","article-title":"Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study","volume":"65","author":"Novitskaya","year":"2023","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0062","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200460","article-title":"Cenobamate monotherapy for focal epilepsy: a single-center retrospective study","volume":"15","author":"Zengin","year":"2025","journal-title":"Neurol Clin Pract"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0063","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/epi.18308","article-title":"A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies","volume":"66","author":"Buhleier","year":"2025","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0064","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/epi.18426","article-title":"Aledo-Serrano A. Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome","volume":"66","author":"Cagigal","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2025.11.016","article-title":"Efficacy and safety of cenobamate in developmental and epileptic encephalopathies: a systematic review and meta-analysis","volume":"134","author":"Samanta","year":"2026","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0066","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200133","article-title":"Cenobamate in generalized epilepsy and combined generalized and focal epilepsy","volume":"13","author":"Agashe","year":"2023","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0067","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","article-title":"Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study","volume":"38","author":"Serrano-Castro","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2026.04.011_bib0068","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2022.01.001","article-title":"Initial real-world experience with cenobamate in adolescents and adults: a single center experience","volume":"129","author":"Elliott","year":"2022","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2026.04.011_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108679","article-title":"Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study","volume":"130","author":"Varughese","year":"2022","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0070","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/epi4.13060","article-title":"Efficacy of add-on cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis","volume":"9","author":"Schulze-Bonhage","year":"2024","journal-title":"Epilepsia Open"},{"issue":"8","key":"10.1016\/j.seizure.2026.04.011_bib0071","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/epi.17662","article-title":"Sudden unexpected death in epilepsy during cenobamate clinical development","volume":"64","author":"Rosenfeld","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0073","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","article-title":"A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis","volume":"118","author":"Mulheron","year":"2024","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0074","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2025.5625","article-title":"Comparative effectiveness of brivaracetam, cenobamate, lacosamide, and perampanel in focal epilepsy","volume":"83","author":"Cerulli Irelli","year":"2026","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2026.04.011_bib0076","series-title":"A summary of antiseizure medications available in the United States","article-title":"American Epilepsy Society Treatments Committee","author":"Vossler","year":"2024"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0077","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","article-title":"Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial","volume":"75","author":"French","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0078","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","volume":"54","author":"Van Paesschen","year":"2013","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0079","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","article-title":"Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial","volume":"55","author":"Ryvlin","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","article-title":"Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial","volume":"55","author":"Biton","year":"2014","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2026.04.011_bib0081","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","article-title":"A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures","volume":"56","author":"Klein","year":"2015","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0082","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2026.04.011_bib0083","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"2-3","key":"10.1016\/j.seizure.2026.04.011_bib0084","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2026.04.011_bib0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2026.04.011_bib0086","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0087","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.04.011_bib0088","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.04.011_bib0089","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: a randomized, double-blind, placebo-controlled study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2026.04.011_bib0090","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2026.04.011_bib0091","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.seizure.2026.04.011_bib0092","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2026.04.011_bib0093","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:20:07Z","timestamp":1778797207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":91,"alternative-id":["S1059131126001020"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cenobamate: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}